JP2016516062A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516062A5 JP2016516062A5 JP2016503089A JP2016503089A JP2016516062A5 JP 2016516062 A5 JP2016516062 A5 JP 2016516062A5 JP 2016503089 A JP2016503089 A JP 2016503089A JP 2016503089 A JP2016503089 A JP 2016503089A JP 2016516062 A5 JP2016516062 A5 JP 2016516062A5
- Authority
- JP
- Japan
- Prior art keywords
- excipient
- pharmaceutical composition
- ionic complex
- cationic polypeptide
- dspe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 125000002091 cationic group Chemical group 0.000 claims description 19
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 125000000129 anionic group Chemical group 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 2
- 239000008135 aqueous vehicle Substances 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 150000003077 polyols Chemical class 0.000 claims 2
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 claims 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229920000831 ionic polymer Polymers 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792440P | 2013-03-15 | 2013-03-15 | |
| US61/792,440 | 2013-03-15 | ||
| PCT/US2014/029421 WO2014144842A2 (en) | 2013-03-15 | 2014-03-14 | Pharmaceutical compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019104944A Division JP2019189619A (ja) | 2013-03-15 | 2019-06-05 | 医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516062A JP2016516062A (ja) | 2016-06-02 |
| JP2016516062A5 true JP2016516062A5 (enExample) | 2018-07-05 |
| JP6538025B2 JP6538025B2 (ja) | 2019-07-03 |
Family
ID=50732290
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503089A Active JP6538025B2 (ja) | 2013-03-15 | 2014-03-14 | 医薬組成物 |
| JP2019104944A Pending JP2019189619A (ja) | 2013-03-15 | 2019-06-05 | 医薬組成物 |
| JP2022023265A Pending JP2022065117A (ja) | 2013-03-15 | 2022-02-17 | 医薬組成物 |
| JP2024169338A Pending JP2025004067A (ja) | 2013-03-15 | 2024-09-27 | 医薬組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019104944A Pending JP2019189619A (ja) | 2013-03-15 | 2019-06-05 | 医薬組成物 |
| JP2022023265A Pending JP2022065117A (ja) | 2013-03-15 | 2022-02-17 | 医薬組成物 |
| JP2024169338A Pending JP2025004067A (ja) | 2013-03-15 | 2024-09-27 | 医薬組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11129869B2 (enExample) |
| EP (2) | EP2970389B1 (enExample) |
| JP (4) | JP6538025B2 (enExample) |
| KR (1) | KR102378943B1 (enExample) |
| CN (3) | CN115957297A (enExample) |
| AU (5) | AU2014228460B2 (enExample) |
| BR (1) | BR112015023409B1 (enExample) |
| CA (2) | CA2906782C (enExample) |
| DK (1) | DK2970389T3 (enExample) |
| ES (1) | ES2825076T3 (enExample) |
| FR (1) | FR21C1059I2 (enExample) |
| IL (2) | IL241378B (enExample) |
| NL (1) | NL301149I2 (enExample) |
| NO (1) | NO2021051I1 (enExample) |
| PL (1) | PL2970389T3 (enExample) |
| PT (1) | PT2970389T (enExample) |
| RU (1) | RU2690377C2 (enExample) |
| WO (1) | WO2014144842A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2732077T3 (es) | 2011-12-29 | 2019-11-20 | Rhythm Pharmaceuticals Inc | Método para tratar trastornos asociados con el receptor de melanocortina-4 en portadores heterocigotos |
| EP2970389B1 (en) | 2013-03-15 | 2020-08-19 | Rhythm Pharmaceuticals, Inc. | Pharmaceutical compositions |
| CN118240012A (zh) * | 2013-03-15 | 2024-06-25 | 节奏制药公司 | 肽组合物 |
| BR112015025968A2 (pt) | 2013-04-11 | 2018-01-09 | Univ Vanderbilt | poliplexos |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| ES2985734T3 (es) * | 2015-09-30 | 2024-11-07 | Rhythm Pharmaceuticals Inc | Método de tratamiento de trastornos asociados a la vía del receptor de la melanocortina-4 |
| JP6701572B2 (ja) * | 2016-07-05 | 2020-05-27 | 株式会社リコー | インク、収容容器、画像形成方法及び画像形成装置 |
| RU2762607C2 (ru) | 2016-09-13 | 2021-12-21 | Аллерган, Инк. | Стабилизированные небелковые композиции клостридиального токсина |
| EP3596107A1 (en) | 2017-03-15 | 2020-01-22 | Novo Nordisk A/S | Bicyclic compounds capable of binding to melanocortin 4 receptor |
| HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
| JP7710707B2 (ja) * | 2017-11-15 | 2025-07-22 | リズム ファーマシューティカルズ， インコーポレイテッド | 持続放出ペプチド製剤 |
| US20210221867A1 (en) | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
| WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
| KR102087634B1 (ko) * | 2018-10-11 | 2020-03-11 | (주)바이텍 | 항비만용 조성물 |
| CR20210363A (es) * | 2019-01-04 | 2021-12-10 | Kineta Chronic Pain Llc | Análogos de péptidos de canotoxina y usos para el tratamiento del dolor y de las afecciones inflamatorias |
| MX2022009844A (es) | 2020-02-18 | 2022-09-05 | Novo Nordisk As | Composiciones y usos del peptido similar al glucagon-1 (glp-1). |
| CN111718408A (zh) * | 2020-07-06 | 2020-09-29 | 成都圣诺生物制药有限公司 | 一种Setmelanotide的制备方法 |
| WO2023028538A1 (en) * | 2021-08-24 | 2023-03-02 | The Regents Of The University Of Michigan | Mc4r agonist peptides |
| WO2023080712A1 (ko) * | 2021-11-05 | 2023-05-11 | ㈜아이엠디팜 | 신규한 서방성 지질 전구 제제 및 이를 포함하는 서방성 주사용 약학 조성물 |
| WO2023247999A1 (en) * | 2022-06-24 | 2023-12-28 | Mainline Biosciences (Shanghai) Co., Ltd. | Peptidic pain modulators and methods for producing and using the same |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849704A (en) * | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
| WO1994026251A1 (en) * | 1993-05-07 | 1994-11-24 | Sequus Pharmaceuticals, Inc. | Subcutaneous liposome delivery method |
| US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5731408A (en) * | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
| US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US20070185032A1 (en) * | 1996-12-11 | 2007-08-09 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US7176279B2 (en) | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
| JP2005504715A (ja) | 2000-12-29 | 2005-02-17 | アドバンスト インハレーション リサーチ，インコーポレイテッド | 持続放出特性を有する吸入用粒子 |
| EP1441750A4 (en) | 2001-07-11 | 2006-10-18 | Palatin Technologies Inc | LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR |
| US20040097419A1 (en) * | 2002-11-19 | 2004-05-20 | Holger Petersen | Organic compounds |
| FR2851563B1 (fr) | 2003-02-26 | 2005-04-22 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
| FR2852957B1 (fr) | 2003-03-31 | 2005-06-10 | Sod Conseils Rech Applic | Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament |
| JP2006527773A (ja) * | 2003-06-19 | 2006-12-07 | イーライ リリー アンド カンパニー | メラノコルチン受容体４（ｍｃ４）作用薬とその用途 |
| FR2862971B1 (fr) | 2003-11-28 | 2006-03-24 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
| KR100638041B1 (ko) | 2003-12-24 | 2006-10-23 | 주식회사 삼양사 | 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법 |
| FR2872165B1 (fr) | 2004-06-24 | 2006-09-22 | Sod Conseils Rech Applic | Nouveaux derives de pyrimido-benzimidazole |
| EP2548568B1 (en) * | 2005-07-08 | 2018-01-10 | Ipsen Pharma | Melanocortin receptor ligands |
| RU2401841C2 (ru) | 2005-07-08 | 2010-10-20 | Ипсен Фарма С.А.С. | Лиганды рецепторов меланокортинов |
| TWI364290B (en) | 2007-05-25 | 2012-05-21 | Ipsen Pharma Sas | Melanocortin receptor ligands modifled with hydantoin |
| TW200848424A (en) | 2007-06-15 | 2008-12-16 | Sod Conseils Rech Applic | Cyclic peptide melanocortin receptor ligands |
| CN103316345B (zh) | 2007-11-05 | 2016-05-18 | 益普生制药股份有限公司 | 黑皮质素治疗胰岛素敏感的应用 |
| US20090305960A1 (en) * | 2008-06-09 | 2009-12-10 | Palatin Technologies, Inc | Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669 |
| AU2009262263B2 (en) * | 2008-06-25 | 2014-08-14 | Endo Pharmaceuticals Solutions Inc. | Octreotide implant having a release agent |
| CN101439182B (zh) * | 2008-12-18 | 2012-02-01 | 北京大学 | 一种生长抑素受体介导的肿瘤靶向药物组合物 |
| UY32690A (es) * | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| NZ596617A (en) * | 2009-06-08 | 2014-04-30 | Palatin Technologies Inc | Melanocortin receptor-specific peptides |
| JP2013501053A (ja) | 2009-08-05 | 2013-01-10 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | 脂質異常症を治療するためのメラノコルチンの使用 |
| RU2548753C2 (ru) | 2009-11-16 | 2015-04-20 | Ипсен Фарма С.А.С. | Фармацевтические композиции лигандов рецепторов меланокортинов |
| US20120226018A1 (en) | 2009-11-16 | 2012-09-06 | Ipsen Pharma, S.A.S. | Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 |
| KR102038677B1 (ko) | 2011-06-14 | 2019-10-30 | 입센 파마 에스.에이.에스 | 활성 성분으로 멜라노코르틴 수용체 리간드를 함유하는 지속-방출형 조성물 |
| JP2013046596A (ja) | 2011-08-29 | 2013-03-07 | Alpha-Nano-Medica Co Ltd | 新規な複合体、それを含有する医薬及び癌の治療方法 |
| WO2013033838A1 (en) * | 2011-09-09 | 2013-03-14 | Pharmagap Inc. | Liposomal formulations of cationic peptides and uses thereof |
| EP2705835A1 (en) | 2012-06-08 | 2014-03-12 | Ipsen Pharma S.A.S. | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
| CN118240012A (zh) * | 2013-03-15 | 2024-06-25 | 节奏制药公司 | 肽组合物 |
| EP2970389B1 (en) * | 2013-03-15 | 2020-08-19 | Rhythm Pharmaceuticals, Inc. | Pharmaceutical compositions |
-
2014
- 2014-03-14 EP EP14724574.0A patent/EP2970389B1/en active Active
- 2014-03-14 JP JP2016503089A patent/JP6538025B2/ja active Active
- 2014-03-14 BR BR112015023409-7A patent/BR112015023409B1/pt active IP Right Grant
- 2014-03-14 CA CA2906782A patent/CA2906782C/en active Active
- 2014-03-14 PL PL14724574T patent/PL2970389T3/pl unknown
- 2014-03-14 US US14/775,911 patent/US11129869B2/en active Active
- 2014-03-14 WO PCT/US2014/029421 patent/WO2014144842A2/en not_active Ceased
- 2014-03-14 PT PT147245740T patent/PT2970389T/pt unknown
- 2014-03-14 EP EP20185463.5A patent/EP3778623A1/en active Pending
- 2014-03-14 CN CN202211043877.XA patent/CN115957297A/zh active Pending
- 2014-03-14 CN CN201480026783.9A patent/CN105518021A/zh active Pending
- 2014-03-14 CA CA3209602A patent/CA3209602A1/en active Pending
- 2014-03-14 DK DK14724574.0T patent/DK2970389T3/da active
- 2014-03-14 ES ES14724574T patent/ES2825076T3/es active Active
- 2014-03-14 RU RU2015143965A patent/RU2690377C2/ru active
- 2014-03-14 KR KR1020157029620A patent/KR102378943B1/ko active Active
- 2014-03-14 AU AU2014228460A patent/AU2014228460B2/en active Active
- 2014-03-14 CN CN202211043853.4A patent/CN115957296A/zh active Pending
-
2015
- 2015-09-09 IL IL241378A patent/IL241378B/en unknown
-
2019
- 2019-01-08 AU AU2019200101A patent/AU2019200101B2/en active Active
- 2019-06-05 JP JP2019104944A patent/JP2019189619A/ja active Pending
-
2021
- 2021-04-30 AU AU2021202699A patent/AU2021202699A1/en not_active Abandoned
- 2021-08-13 US US17/401,929 patent/US12285460B2/en active Active
- 2021-12-03 NO NO2021051C patent/NO2021051I1/no unknown
- 2021-12-06 NL NL301149C patent/NL301149I2/nl unknown
- 2021-12-13 IL IL288961A patent/IL288961A/en unknown
- 2021-12-14 FR FR21C1059C patent/FR21C1059I2/fr active Active
-
2022
- 2022-02-17 JP JP2022023265A patent/JP2022065117A/ja active Pending
-
2023
- 2023-07-12 AU AU2023204625A patent/AU2023204625A1/en not_active Abandoned
-
2024
- 2024-09-27 JP JP2024169338A patent/JP2025004067A/ja active Pending
-
2025
- 2025-08-05 AU AU2025213562A patent/AU2025213562A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516062A5 (enExample) | ||
| KR101834024B1 (ko) | 치환된 베타―시클로덱스트린에 의해 안정화된 포사코나졸 정맥내 용액 제제 | |
| JP5723030B2 (ja) | エキノカンジン系抗真菌剤であるミカファンギンを含む薬用組成物およびその製造方法と用途 | |
| JP2014040441A5 (enExample) | ||
| JP2017105802A5 (enExample) | ||
| US10537520B2 (en) | Stable liquid formulations of melphalan | |
| JPWO2015190378A1 (ja) | 安定なアダリムマブ水性製剤 | |
| JP6736765B2 (ja) | ベンダムスチン溶液製剤 | |
| UA124818C2 (uk) | Композиція для ін'єкції | |
| US10610532B2 (en) | Liquid formulations of fosaprepitant | |
| CN105796482B (zh) | 紫杉醇缓释温敏凝胶及其制备方法 | |
| CN107810000A (zh) | 来氟米林的可注射药物组合物 | |
| JP6347784B2 (ja) | 神経筋遮断薬の安定化水性組成物 | |
| KR102160866B1 (ko) | 액상 의약 제제 | |
| US20180071393A1 (en) | Stable intravenous formulation | |
| JP5070670B2 (ja) | Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物の凍結乾燥製剤およびその製造方法 | |
| US11628137B2 (en) | Parenteral formulation comprising siponimod | |
| JPWO2009123099A1 (ja) | ガチフロキサシン含有水性液剤 | |
| US20190070136A1 (en) | Parenteral compositions of carmustine | |
| KR100973470B1 (ko) | 칼시토닌-폴리포스페이트의 복합체 및 그의 제조방법 | |
| WO2011071853A2 (en) | Parenteral formulation of clopidogrel | |
| JPWO2013154045A1 (ja) | 注射剤用組成物 | |
| EP2968595A2 (en) | Voriconazole formulations | |
| KR20140147336A (ko) | 도세탁셀을 함유하는 액상 주사용 조성물 | |
| WO2018235015A1 (en) | Tropicamide-based ophthalmic formulations |